June 25, 2018 4:11 PM ET


Company Overview of Cerecor Inc.

Company Overview

Cerecor Inc., a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Veripred, and Ulesfia for the treatment of inflammation of the skin, joints, lungs, and other organs, as well as asthma, allergies, arthritis, and head lice infestation. It also offers Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension; and Flexichamber. The company is developing CERC-301, an orphan neurological indication for controlling neurologic adaptation; CERC-611, a drug candidate for the treatment of partial-onset seizures in epilepsy; and two preclinic...

400 East Pratt Street

Suite 606

Baltimore, MD 21202

United States

Founded in 2011

38 Employees



Key Executives for Cerecor Inc.

Cerecor Inc. does not have any Key Executives recorded.

Cerecor Inc. Key Developments

Cerecor Inc. Approves Amendment to Certificate and Bylaws

Cerecor Inc. at its AGM held on May 15, 2018 approved an amendment to the company's Certificate and Bylaws to declassify the Board, to eliminate the provisions requiring a super-majority stockholder vote to amend the Bylaws, and to act by majority written consent as long as Armistice Capital LLC owns at least 40% of outstanding stock.

Cerecor Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2018; Provides Earnings Guidance for the Year 2018

Cerecor Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2018. For the quarter, the company reported total revenues, net of $4,483,000 compared to $384,000 a year ago. Loss from operations was $3,492,000 compared to $1,899,000 a year ago. Net loss before taxes was $3,860,000 compared to $1,961,000 a year ago. Net loss was $3,883,000 compared to $1,961,000 a year ago. Net loss per share of common stock, basic and diluted was $0.12 compared to $0.19 a year ago. LBITDA was $2,692,000 compared to $1,897,000 a year ago. Adjusted LBITDA was $1,435,000 compared to $1,565,000 a year ago. Based upon current performance, the company has increased its full-year 2018 net revenue guidance to $16 to $18 million and projects its 2018 adjusted EBITDA to be approximately break-even.

Cerecor Seeks Acquisitions

Cerecor Inc. (NasdaqCM:CERC) plans acquisitions in year ahead, as said by the Chief Executive officer Peter Greenleaf.

Similar Private Companies By Industry

Company Name Region
Praetego, Inc. United States
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

February 12, 2018
Avadel Pediatric Portfolio
November 17, 2017
TRx Pharmaceuticals, LLC
August 14, 2017
Cerecor Inc., CERC-501

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Cerecor Inc., please visit www.cerecor.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.